New hope for colorectal cancer: immune booster plus chemotherapy tested

NCT ID NCT07359456

Not yet recruiting Disease control Sponsor: UNICANCER Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether adding the immune-boosting drug ivonescimab to standard chemotherapy (FOLFIRI) helps people with advanced colorectal cancer live longer without their cancer growing. It compares this new combination to the current standard of FOLFIRI plus bevacizumab. The study includes 130 adults whose cancer has not spread to the liver and who have already tried one prior treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ivonescimab (a drug that helps the immune system fight cancer) combined with FOLFIRI chemotherapy
What this could lead to: If it works, this could offer a more effective second-line treatment option for people with a common type of advanced colorectal cancer that hasn't spread to the liver.
What could go wrong: This is an early phase 2 trial with only 130 participants, so results may not apply to everyone. The new combination may not work better than the current standard and could have side effects like immune-related reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC COLORECTAL CANCER

Contacts and locations

Locations

CH d'Auxerre

Auxerre, France
CH de Calais

Calais, France
CHRU de Nancy

Nancy, France
CHU de Poitiers

Poitiers, France
CHU de Reims

Reims, France
CHU de Rouen

Rouen, France
Centre François Baclesse

Caen, France
Centre Hospitalier de Beuvry

Beuvry, France
Centre Hospitalier de Valenciennes

Valenciennes, France
Centre Léon Bérard

Lyon, France
Centre Oscar Lambret

Lille, France
Gustave Roussy

Villejuif, France
Hôpital Européen de Marseille

Marseille, France
Hôpital Privé des côtes d'Armor

Plérin, France
Hôpital Saint Antoine - APHP

Paris, France
Hôpital Saint Louis - APHP

Paris, France
Hôpital la Timone

Marseille, France
Institut Andrée Dutreix

Coudekerque-Branche, France
Institut Jean Godinot

Reims, France
Institut Paoli Calmettes

Marseille, France
Institut de Cancérologie de l'Ouest - Site René Gauducheau

Saint-Herblain, France
Polyclinique Saint Côme

Compiègne, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.